AstraZeneca	**Study Number:** D6130C00003	*Confidential Document*
		As applicable: **Trial Master File Zone:** Trial Management **Artifact: 1. 1. 10**

Title/Reference: A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy

Topic: Results not posted on the EudraCT Registry

Summary: The above mentioned study has been submitted to the authorities, however the study was stopped without any patients being recruited, therefore results will not be posted in the EudraCT registry.

Anneke Ravensbergen, Group Director Study Operations
Full Name, Position

Date

DocuSigned by Anneke Ravensbergen
Anneke Ravensbergen
I am the author of this document
17 January 2022 | 08:47 AST
F646F5C31FEA49C4B953A354FC4B32D3

17 January 2022 | 08:47 AST

DocuSign

Certificate Of Completion

Envelope Id: 6CAC92737C884951AEA0FE2297B3B720
Status: Completed
Subject: Please DocuSign: D6130C00003 NTF EudraCT Results_12Jan2022.docx
Source Envelope:
Document Pages: 1
Signatures: 1
Certificate Pages: 3
Initials: 0
AutoNav: Enabled
EnvelopeId Stamping: Enabled
Time Zone: (UTC) Dublin, Edinburgh, Lisbon, London

Envelope Originator:
Onye Michelle
1800 Concord Pike FOP1-237
Wilmington, DE 19850
Michelle.Onye@astrazeneca.com
IP Address: 165.225.8.172

Record Tracking

Status: Original
1/13/2022 2:30:18 PM
Holder: Onye Michelle
Michelle.Onye@astrazeneca.com
Location: DocuSign

Signer Events	Signature	Timestamp
Anneke Ravensbergen anneke.ravensbergen@acerta-pharma.com Group Associate Director Study Operations Security Level: Email, Account Authentication (Required)	Anneke Ravensbergen Signature Adoption: Pre-selected Style Signature ID: F646F5C3-1FEA-49C4-B953-A354FC4B32D3 Using IP Address: 147.161.172.170 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I am the author of this document	Sent: 1/13/2022 2:31:15 PM Viewed: 1/13/2022 4:01:56 PM Signed: 1/17/2022 12:47:22 PM
Electronic Record and Signature Disclosure: Accepted: 1/13/2022 4:01:56 PM ID: 619990e1-7e85-45b6-b1f8-5995d12c9362		

In Person Signer Events	Signature	Timestamp

Editor Delivery Events	Status	Timestamp

Agent Delivery Events	Status	Timestamp

Intermediary Delivery Events	Status	Timestamp

Certified Delivery Events	Status	Timestamp

Carbon Copy Events	Status	Timestamp

Witness Events	Signature	Timestamp

Notary Events	Signature	Timestamp

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	1/13/2022 2:31:15 PM
Certified Delivered	Security Checked	1/13/2022 4:01:56 PM
Signing Complete	Security Checked	1/17/2022 12:47:22 PM
Completed	Security Checked	1/17/2022 12:47:22 PM

Payment Events	Status	Timestamps

Electronic Record and Signature Disclosure

I hereby consent to that AstraZeneca Worldwide https://www.astrazeneca.com may disclose personal information such as; full name, email address, and any other information you may supply on the electronic form to AstraZeneca affiliates and third party service providers throughout the world in relation to the handling and administration of the Electronic Signature Service solution. This consent relates to any electronic records or signatures associated with the electronic contract.

AstraZeneca and the third party administering this service store and process personal information that AstraZeneca collects from you for the purposes of operating the Electronic Signature Service solution.

This also applies after termination of the Agreement. Processing of your personal information will be done in accordance with applicable law.

You may request access to your personal data and withdraw agreement to this processing at any time by contacting us in writing at docusign-support@astrazeneca.com.

Personal details and electronic signatures of signatories contained in contracts cannot be removed once the contract has been executed and will remain part of such contracts until these are destroyed in accordance with applicable law and AstraZeneca internal data retention policies.